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ABSTRACT
The patients presenting with metastatic solid tumors remains with poor prognosis. Despite advances in
treatment and better understanding of the biological pathway during the past two decades, outcome remains
often very poor. On the other hand, allogeneic stem cell transplantation has been established as a potent
antitumoral immunotherapy in various hematological malignancies. Preliminary results confirm that graft
versus tumor effect does exist. The main challenge is now to transform this biological and clinical effect into
a real clinical benefit in term of curability and survival.
© 2007 American Society for Blood and Marrow Transplantation
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mNTRODUCTION
At the conclusion of a recent meeting in Stresa,
taly that gathered medical oncologists and investiga-
ors worldwide involved in allogeneic stem cell trans-
lantation (allo-SCT) for nonhematologic malignancies
1], Marco Bregni highlighted the following points:
. Allografting in solid tumors is feasible with limited
toxicities and transplant-related mortality (TRM).
However, further improvement of toxicities and
TRM is needed if the procedure is to become
accepted by the oncology community, particularly
in diseases for which many therapeutic options
exist (eg, breast cancer and renal cell carcinoma).
. A graft-versus-tumor (GVT) effect can be docu-
mented in various solid tumors. Further research is
needed to translate the GVT effect into meaning-
ful clinical beneﬁts.
. Advanced renal cancer appears to be the most
promising solid tumor for allografting. Other tu-
mors with promising response rates are breast can-
cer and ovarian cancer.
. There is some evidence that small-volume disease
achieved by tumor debulking before transplantation
or by cytoreduction with chemotherapy with or with-
out autologous transplantation may be of beneﬁt.
. Targeting the immune response to the tumor with
speciﬁc immune lymphocytes, natural killer (NK)
cells, or vaccines, is a promising area of research.
. Unrelated or haploidentical donor transplantation for
solid tumors remains in the developmental phase.
. The search for target antigens of the immune re-
sponse should be a translational research endpoint
included in every clinical trial. pThese conclusions were promulgated after a 2-day
eeting during which medical oncologists and allo-
CT investigators exchanged their experiences with
iological and clinical aspects of tumor development
nd treatment. These exchanges facilitated a compre-
ensive overview of achievements and unanswered
uestions in the ﬁeld and provided a basis for future
irections. Three diseases were discussed in detail:
enal cell carcinoma (RCC), breast cancer (BRC), and
varian carcinoma (OVC). These were chosen be-
ause high numbers of patients have been transplanted
or these indications, and because consistent evidence
f tumor response is documented.
ENAL CELL CARCINOMA
The initial pioneering study by Childs et al [2]
chieved response rates of up to 53% in patients who
ad failed other forms of immunotherapy (mainly re-
ombinant interleukin-2 and/or interferon [INF]-)
nd who received allo-SCT after reduced-intensity
onditioning including cyclophosphamide and ﬂu-
arabine, from an HLA-identical sibling. Childs et al
ecently updated their results; currently, 75 patients
ith a median of 2 metastatic sites have undergone
ransplantation. Graft-versus-host disease (GVHD)
rophylaxis consisted of cyclosporine A, given alone in
he initial cohort and later in combination with my-
ophenolate mofetil or mini-dose methotrexate. Tu-
or responses (frequently preceded by tumor pro-
ression) were delayed in onset (130-160 days after
ransplantation), sometimes occurring after the ad-
inistration of posttransplantation INF-, even in
atients who had previously failed this treatment. In a
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D. Blaise and M. Bregni74ew cases, responses were durable. Overall, sustained
ngraftment was achieved in 74 of 75 patients. Acute
nd chronic GVHD were observed in approximately
0% of the patients. Death from TRM occurred in
% of the patients, half of whom died from compli-
ations related to GVHD. To date, 38% of the pa-
ients have exhibited radiographic evidence of tumor
egression (27% partial remission [PR]; 9% complete
emission [CR]), with responses occurring at a median
f day 160 after transplantation (range, days 30-425).
everal prognostic factors are associated with re-
ponse, including a limited number of metastatic sites,
xclusive lung metastases, clear cell histology, and
slow” progressive disease. Liver metastases appear to
e a negative prognostic factor (an 11% response rate
n those who underwent transplantation for liver me-
astasis), whereas lung metastasis was a positive factor
a 55% response rate). Responses in nonclear histol-
gy, including papillary tumors, were not observed.
rtz et al [3] reviewed the literature and the Chicago
xperience and found that in 14 reported studies, a
otal of 163 evaluable patients had 32 PRs and 7 CRs,
ith an overall response rate of 24%.
REAST CARCINOMA
The ﬁrst cases of tumor regression after allo-SCT
ere observed in patients treated for metastatic breast
ancer [4,5]. The ﬁrst series of patients was reported
y Ueno et al [6] from the M.D. Anderson Cancer
enter. Ten patients with liver or bone marrow me-
astases received a standard conditioning regimen (cy-
lophosphamide, BCNU, and thiotepa). Three objec-
ive responses after tapering of immunosuppression (1
R, 2 PRs) were documented. This ﬁnding was later
onﬁrmed by other investigators [7-10]. The largest un-
ublished series was presented by Ueno and Nieder-
ieser on behalf of the Center for International Blood
nd Marrow Transplantation Research (CIBMTR)
nd the European Group for Blood and Marrow
ransplantation (EBMT).1 A total of 75 patients who
eceived an allograft between 1992 and 2000 from a
LA-identical or unrelated donor from 16 centers
ere included. A GVT effect was suggested by disease
esponse according to a preliminary data analysis.
VARIAN CARCINOMA
Although the ﬁrst patient receiving an allo-SCT
as reported almost 50 years ago [11], the ﬁrst patient
eries documenting a GVT effect was reported only
ecently [12]. On behalf of the EBMT, Bay et al [12]
escribed 24 patients who had undergone allo-SCT
with 2 receiving 2 allo-SCTs), 2 with a myeloablative
egimen (cytoxan  busulfan) and 22 with 1 of 3
onmyeloablative ﬂudarabine-based regimens. Me-
ian age was 51 years. Patients received allo-SCT at a pedian of 41 months from diagnosis; disease status at
ime of transplantation was progressive disease (PD)
n 9 patients, stable disease (SD) in 10 patients, PR in
patients, and CR in 1 patient. The graft source was
one marrow in 5 (19%) and peripheral blood stem
ells in the other 21 (81%). Engraftment and full
onor chimerism were rapid and complete, irrespec-
ive of the conditioning. Acute GVHD was observed
n 15 patients ( grade 2 in 11 cases [44%]), corre-
ated with tumor response in 8 cases. Chronic GVHD
ccurred in 8 patients, in 3 after donor lymphocyte
nfusion (DLI). Seven patients received DLI for PD,
nd 3 achieved PR associated with chronic GVHD.
esponses were as follow: 0 CR, 13 PR, 7 SD, and 4
D. TRM was relatively high (6 patients; 28%), and
6 patients died from disease progression. The me-
ian survival time was 10 months.
ELANOMA
Metastatic melanoma was initially a favored area
f investigation for allo-SCT, due mainly to the pos-
tive results obtained after nonallogeneic immuno-
herapy based on cytokine [13] or vaccine approaches
14]. However, the absence of tumor response has
onsistently been reported [15]. Melanoma is now
onsidered a contraindication for allo-SCT.
THER TUMORS
Although other tumors are of interest, reports on
hese remain anecdotal. However, preliminary clinical
vidence of a GVT effect has been described in soft
issue sarcoma, pancreatic cancer, prostate cancer, and
olon cancer [1,16].
URRENT DIFFICULTIES
It is reasonable to conclude that GVT effects occur in
iverse metastatic solid tumors. Nevertheless, the number
f patients with solid tumors referred for allo-SCT remains
ow for several reasons, which must be taken into consid-
ration if recruitment is to be improved [17].
First, most ST patients receiving allo-SCT are not
ncluded in clinical trials. In 2004, published series
ccounted for only 200 patients, whereas almost 1000
llo-SCT patients were reported to the EBMT alone.
his has reduced the impact of allo-SCT data and has
romoted a “last-chance” transplantation approach
or end-stage patients already nonresponsive to other
reatments. Besides being of no beneﬁt to the patients,
his strategy reinforces the perception that allo-SCT
s unsuccessful, discouraging clinical trials in more
ppropriate disease settings.
Second, there are multiple failures of communica-
ion between medical oncologists and the transplan-
ation community. The failure of autologous trans-
lantation to prolong survival in women with breast
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Allogeneic Stem Cell Transplantation for Solid Tumors 75ancer has had a deleterious impact on the referral of
atients with solid tumors for investigational allo-
CT trials. Many practicing oncologists who could
efer patients for allo-SCT do not understand the
mmunotherapeutic nature of the allograft. In addi-
ion, new targeted therapies are becoming available to
ncologists, notably for RCC. There is an unproven
ssumption that these agents will be as spectacular as
matinib has been in treating chronic myeloid leuke-
ia. Although patients may fail targeted treatments,
hese new drugs remain attractive because they are less
oxic than allo-SCT. Furthermore, outside of the
ransplantation community, the continuing trend to-
ard decreased TRM is little known and underesti-
ated. Response rates of patients after allo-SCT re-
ain within the range of 15%–25%. Although this
nding is encouraging considering the disease status
f most patients, there are very few CRs, and although
urvival is sometimes prolonged, most patients even-
ually die from progressive disease. Clearly, medical
ncologists would refer more patients if the results
ere better. Improved outcome could be anticipated if
ewer patients in advanced-stage disease were re-
erred, given the anticipated improved therapeutic ef-
ect and lower transplant-related toxicity [5].
Despite its limitations, however, allo-SCT adds a
nique immunotherapeutic component with the
romise of cure. Our challenge is both to transform
llo-SCT into an efﬁcient therapy and to communi-
ate our optimism to the oncologic community.
HE WAY FORWARD
atient Selection
Adequate selection of patients with poor prognosis at
n early stage of disease is mandatory to achieve better
umor control and reduce toxicity, and it is the only
ikely way to achieve cure. Better markers of disease
rognosis and treatment response are needed to identify
hose patients most likely to beneﬁt from allo-SCT.
ebulking
Optimal strategies for decreasing tumor load at
he time of transplantation by surgical or chemother-
py debulking should be deﬁned. Targeted therapies
ay also be valuable, but such treatment must be
elected according to the precise molecular pathology.
ell Therapy
NK cells, T-regulatory cells, and CD8 cytotoxic
cells are potential candidates in complementary
trategies to achieve better antitumor effects.
mproved Understanding of Target Antigens and
mmune Mechanisms
Identiﬁcation of the antigens mediating GVT could
ead to vaccine or adoptive cell transfer strategies that
ould signiﬁcantly improve the antitumor effect.idening of the Donor Repertoire
Because most patients do not have an HLA-iden-
ical sibling donor, transplants from alternative donors
hould be incorporated into clinical trials of allo-SCT
o treat solid tumors.
EFERENCES
1. Bregni M, Ueno NT, Childs R. The Second International
Meeting on Allogeneic Transplantation in Solid Tumors. Bone
Marrow Transplant. 2006;38(8):527-537.
2. Childs R, Chernoff A, Contentin N, et al. Regression of metastatic
renal cell carcinoma after nonmyeloablative allogeneic peripheral
blood stem cell transplantation. N Engl J Med. 2000;343:750-758.
3. Artz AS, Van Besien K, Zimmerman T, et al. Long-term
follow-up of nonmyeloablative allogeneic stem cell transplan-
tation for renal cell carcinoma: the University of Chicago ex-
perience. Bone Marrow Transplant. 2004;38(8):527-537.
4. Ben-Yosef R, Or R, Nagler A, et al. Graft-versus-tumour and graft-
versus-leukaemia effects in a patient with concurrent breast cancer
and acute myelocytic leukaemia. Lancet. 1996;348:1242-1243.
5. Eibl B, Schwaighofer H, Nachbaur D, et al. Evidence for a
graft-versus-tumor effect in a patient treated with marrow ab-
lative chemotherapy and allogeneic bone marrow transplanta-
tion for breast cancer. Blood. 1996;88:1501-1508.
6. Ueno NT, Rondon G, Mirza NQ, et al. Allogeneic peripheral
blood progenitor cell transplantation for poor-risk patients with
metastatic breast cancer. J Clin Oncol. 1998;16:986-993.
7. Bregni M, Dodero A, Peccatori J, et al. Nonmyeloablative
conditioning followed by hematopoietic cell allografting and
donor lymphocyte infusions for patients with metastatic renal
and breast cancer. Blood. 2002;99:4234-4236.
8. Bishop MR, Fowler DH, Marchigiani D, et al. Allogeneic
lymphocytes induce tumor regression of advanced metastatic
breast cancer. J Clin Oncol. 2004;22:3886-3892.
9. Blaise D, Bay JO, Faucher C, et al. Reduced-intensity prepar-
ative regimen and allogeneic stem cell transplantation for ad-
vanced solid tumors. Blood. 2004;103:435-441.
0. Carella AM, Beltrami G, Corsetti MT, et al. Reduced-intensity
conditioning for allograft after cytoreductive autograft in met-
astatic breast cancer. Lancet. 2005;366:318-320.
1. Thomas ED, Lochte HL Jr, LuWC, et al. Intravenous infusion
of bone marrow in patients receiving radiation and chemother-
apy. N Engl J Med. 1957;257:491-496.
2. Bay JO, Fleury J, Chouﬁ B, et al. Allogeneic hematopoietic
stem cell transplantation in ovarian carcinoma: results of ﬁve
patients. Bone Marrow Transplant. 2002;30:95-102.
3. Rosenberg SA. Progress in human tumour immunology and
immunotherapy. Nature. 2001;411:380-384.
4. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy:
moving beyond current vaccines. Nat Med. 2004;10:909-915.
5. Childs R, Bradstock K, Gottlieb D, et al. Non-myeloablative allo-
geneic stem cell transplantation (NST) for metatstatic melanoma:
non-durable chemotherapy responses without clinically meaningful
graft-versus-tumor (GVT) effects. Blood. 2002;100:429a (abstr.).
6. Hentschke P, Barkholt L, UzunelM, et al. Low-intensity condition-
ing and hematopoietic stem cell transplantation in patients with renal
and colon carcinoma. Bone Marrow Transplant. 2003;31:253-261.
7. Gratwohl A, Baldomero H, Schmid O, et al. Change in stem cell
source for hematopoietic stem cell transplantation (HSCT) in Eu-
rope: a report of the EBMT activity survey 2003. Bone Marrow
Transplant. 2005;36:575-590.
